Innovus Pharma’s AllerVarx™ Receives Commercial Approval by Health Canada for the Reduction in Symptoms of Seasonal Allergic Rhinitis
“AllerVarx™ is an excellent complement to our fast growing portfolio of products available within the Canadian market,” said Innovus Pharma President and Chief Executive Officer Dr. Bassam Damaj. “The product will greatly help our customers in that country who are suffering from seasonal allergic rhinitis. AllerVarx™ is our eighth product on the Canadian market including Zestra®, Zestra Glide® and Uxor™ (EjectDelay™) marketed by Orimed Pharma, UriVarx® through our recently announced partnership with Acerus Pharmaceuticals Corporation and Vesele®, Xyralid® and Apeaz™ through our own marketing and sales efforts in that country.”
AllerVarx™ is a patented formulation produced in bilayer tablets with a technology that allows a controlled release of the ingredients. The fast-release layer allows the rapid antihistaminic activity of Perilla. The sustained-release layer enhances Quercetin, Spirulina and Vitamin D3 bioavailability, thanks to its lipidic matrix, and exerts anti-allergic activity spread over time.
AllerVarx™ was studied in a published clinical trial assessing the reduction of both nasal and ocular symptoms in allergic patients, and daily consumption of anti-allergic drugs, over a period of 30 days. AllerVarx™ showed a reduction of approximately 70% in total symptom scores and a reduction of approximately 73% in the use of anti-allergic drugs. There were no side effects noted during the administration of AllerVarx™ and all the patients enrolled finished the study with good compliance.
The World Health Organization (“WHO”) classifies allergies as the fourth most important chronic disease in the world. Allergic Rhinitis (“AR”) is the most common form of non-infectious rhinitis, affecting between 10% and 30% of all adults in the United States, and as many as 40% of U.S. children. Epidemiologic studies show that the prevalence of AR is expected to still be important in the next decades. The World Allergy Organization (“WAO”) has estimated that 400 million people in the world suffer from AR, which remains to a large extent underdiagnosed and undertreated.
AllerVarx™ is a patented formulation produced in bilayer tablets with a technology that allows a controlled release of the ingredients. The fast-release layer allows the rapid antihistaminic activity of Perilla. The sustained-release layer enhances Quercetin, Spirulina and Vitamin D3 bioavailability, thanks to its lipidic matrix, and exerts anti-allergic activity spread over time. For more information on the product please visit www.allervarx.com.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the AllerVarx™ product in Canada if approved in that country, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
Innovus Pharma Investor Relations
Randy Berholtz, +1 858 249 7865
Source: Innovus Pharmaceuticals, Inc.